<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04990908</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL21_0378</org_study_id>
    <nct_id>NCT04990908</nct_id>
  </id_info>
  <brief_title>Systematic Screening for Primary Immunodeficiencies in Patients Admitted for Severe Infection in Pediatric Intensive Care Unit</brief_title>
  <acronym>SPYSI</acronym>
  <official_title>Systematic Screening for Primary Immunodeficiencies in Patients Admitted for Severe Infection in Pediatric Intensive Care Unit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Severe infections in pediatric intensive care unit are not uncommon. Historically, the&#xD;
      diagnosis of hereditary (primary) immune deficiency required a combination of recurrent&#xD;
      clinical signs and biological stigmas. This paradigm is currently being questioned, and grows&#xD;
      the hypothesis of a potential underlying genetic susceptibility in any severe infection. To&#xD;
      date, the proportion of severe infections explained by an underlying immune deficiency is&#xD;
      unknown.&#xD;
&#xD;
      The aim of this prospective study is to assess the incidence of primary immune deficiencies&#xD;
      in children with severe infection, regardless of their etiology.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>number of patients with primary immunodeficiency revealed after a severe infection in pediatric ICU or in neuropediatric unit</measure>
    <time_frame>1 day</time_frame>
    <description>number of patients with primary immunodeficiency revealed after a severe infection in pediatric ICU or in neuropediatric unit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of to evaluate the sensitivity of our systematic screening</measure>
    <time_frame>1 day</time_frame>
    <description>To evaluate the sensitivity of our systematic screening in relation to an approach scrupulously following the indications of other published studies for the screening of primary immunodeficiencies</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The number of immune deficiencies that have no other call point based on the list of warning signs of the Reference Center for Hereditary Immune Deficiencies (CEREDIH)</measure>
    <time_frame>1 day</time_frame>
    <description>The number of immune deficiencies that have no other call point based on the list of warning signs of the Reference Center for Hereditary Immune Deficiencies (CEREDIH)</description>
  </other_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Severe Infection</condition>
  <condition>Severe Immune Deficiency</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Pediatric population&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Inclusion age less than 16 years&#xD;
&#xD;
          -  Inclusion age &gt; 3 months of actual age for term infants and &gt; 3 months for former&#xD;
             preterm infants.&#xD;
&#xD;
          -  Documented severe infection (bacterial, viral, fungal) at the University Hospital&#xD;
             Center of Montpellier, Toulouse or Marseille&#xD;
&#xD;
          -  Severe infections concerned by the study: any infection requiring hospitalization in&#xD;
             pediatric intensive care (more than 24 hours) including:&#xD;
&#xD;
          -  meninges or brain lesions, pleuro-pneumopathy, any infection associated with sepsis&#xD;
             and/or an opportunistic germ, septic shock, etc.&#xD;
&#xD;
          -  Encephalitis and encephalomyelitis of infectious origin&#xD;
&#xD;
          -  Child benefiting from a social security system&#xD;
&#xD;
          -  Collection of parental/legal representative consent&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Undocumented severe infections&#xD;
&#xD;
          -  Acute bronchiolitis&#xD;
&#xD;
          -  Children admitted with isolated SRV bronchiolitis without further complications from&#xD;
             the infection;&#xD;
&#xD;
          -  Previous comorbidity explaining the infection and/or stay in ICU/Continuing Care:&#xD;
             Primary or known secondary immune deficiency; burns; risk factors for non-infectious&#xD;
             epilepsy (encephalopathy, known epilepsy, head trauma), pneumonia caused by swallowing&#xD;
             disorders or tracheotomy or chronic lung disease, asthma, meningitis favored by&#xD;
             cochlear implants, breach of blood-brain barrier or neuromeningetic material, deep&#xD;
             infection on implanted material or within 48h after surgery, cardiovascular&#xD;
             decompensation; any other chronic conditions that may contribute to infection;&#xD;
&#xD;
          -  Inability to obtain consent from parents/legal guardians.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric JEZIORSKI</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric JEZIORSKI</last_name>
    <phone>04 67 33 57 98</phone>
    <phone_ext>33</phone_ext>
    <email>e-jeziorski@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Uhmontpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Jeziorski, MCU-PH</last_name>
      <phone>04 67 33 66 03</phone>
      <phone_ext>33</phone_ext>
      <email>e-jeziorski@chu-montpellier.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 5, 2021</study_first_submitted>
  <study_first_submitted_qc>July 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>genetics</keyword>
  <keyword>screening</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Primary Immunodeficiency Diseases</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

